Compare Franco-Nevada Corporation (FNV) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franco-Nevada Corporation vs HCA Health Inc — how do they compare? Franco-Nevada Corporation trades at $233.84 (market cap $46.80B), while HCA Health Inc trades at $473.93 (market cap $99.75B). The key difference: HCA Health Inc is far larger — about 2.1× Franco-Nevada Corporation's market cap, and Franco-Nevada Corporation pays the higher dividend (0.72%). Which is the better fit depends on your goals — on Pluang, investors hold Franco-Nevada Corporation for 0 Days and HCA Health Inc for 76 Days on average.
| FNV | HCA | |
|---|---|---|
Market Cap | $46.80B | $99.75B |
Volume | 310,692 | 1,083,231 |
Sector | Basic Materials | Health |
52-Week High | $280.82 | $545.13 |
52-Week Low | $183.97 | $361.32 |
Typical Hold Time | 0 Days | 76 Days |
Enterprise Value | $45.79B | $150.29B |
Dividend Yield | 0.72% | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.
The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.
HCA Healthcare's stock trades at $470.44, up 2.58% today, with a bullish technical outlook and strong earnings beats in recent quarters. Revenue grew to $75.60B in 2025, with a net income margin of 8.77%, while the P/E ratio of 15.45 suggests reasonable valuation. Recent news includes an upcoming Q3 2026 earnings call and ongoing legal investigations, creating mixed sentiment.
The outlook is positive due to consistent earnings performance and analyst buy ratings, but risks include high debt levels and regulatory scrutiny. Investment opportunity lies in operational efficiency and demand growth, though investors should monitor legal developments and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Franco-Nevada Corporation
Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).
Read more on FNV →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
